Bremansu OSA-ANDREWS

Dr. Bremansu OSA-ANDREWS

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CZCindy Zhang
Cindy Zhang
VCVictoria Chen
Victoria Chen
BOBremansu OSA-ANDREWS
Bremansu OSA-ANDREWS
JCJing Cao
Jing Cao
Hemoglobin (Hb) defects, or hemoglobinopathies such as thalassemia and structural Hb variants, are among the most prevalent inherited diseases and are associated with significant mortality and morbidity worldwide. Screening for hemoglobinopathies in the primary care setting plays a critical role in enhancing patient outcomes and advancing population health. It promotes awareness, enables early diagnosis and treatment, supports informed reproductive decisions through genetic counseling, and facilitates access to novel therapies such as genetic modifications. Screening approaches for hemoglobinopathies have evolved to reflect regional prevalence, healthcare infrastructure, and ethical considerations. Varying strategies underscore the necessity of tailoring to local contexts, balancing cost, accuracy, accessibility, and social impact. As global migration reshapes population genetics, flexible and equitable screening frameworks are increasingly essential. This review focuses on practical techniques suitable for the screening of Hb defects in primary care. Recent advances and findings in high-performance liquid chromatography, capillary zone electrophoresis, mass spectrometry, point of care testing, and molecular methodologies are covered. In addition, strategies and approaches in multiple regions in the world are reviewed.

Verified
Journal Article
Open access
PDF file
JOJohn O Ogunbileje
John O Ogunbileje
NHNeil Harris
Neil Harris
TWTung Wynn
Tung Wynn
RKReemq Kashif
Reemq Kashif
BSBrian Stover
Brian Stover
BOBremansu OSA-ANDREWS
Bremansu OSA-ANDREWS
The ATP-binding cassette (ABC) transporters are a vast group of 48 membrane proteins, some of which are of notable physiological and clinical importance. Some ABC transporters are involved in functions such as the transport of chloride ions, bilirubin, reproductive hormones, cholesterol, and iron. Consequently, genetic or physiological disruption in these functions is manifested in various disease processes like cystic fibrosis, Tangier disease, and sideroblastic anemia. Among other etiologies, primary sideroblastic anemia results from a genetic mutation in the ATP-binding cassette-7 (ABCB7), a member of the ABC transporter family. There are not many articles specifically tackling the disease processes caused by ABC transporters in detail. Some testing methodologies previously reported in the available literature for investigating sideroblastic anemia need updating. Here, we expound on the relevance of ABCB7 as a clinically important ABC transporter and a rare participant in the disease process of Sideroblastic anemia. The other genetic and secondary etiologies of sideroblastic anemia, which do not involve mutations in the ABCB7 protein, are also described. We review the pathophysiology, clinical course, symptoms, diagnosis, and treatment of sideroblastic anemia with a focus on modern technologies for laboratory testing.

1 October 2025
Verified
Open access
BOBremansu OSA-ANDREWS
Bremansu OSA-ANDREWS
JOJohn O. Ogunbileje
John O. Ogunbileje
NHNeil Harris
Neil Harris
TWTung Wynn
Tung Wynn
Hematological disorders are frequently encountered at the doctor’s office and in the emergency room. Sideroblastic anemia, a rare hematological malady, is characterized by ring sideroblasts in the red blood cells due to accumulation of poorly transported and underutilized iron. Unlike primary sideroblastic anemia which can be conclusively diagnosed through genetic testing, the more common secondary form of the disease requires intricate cascading of several preliminary and confirmatory laboratory testing to determine the accurate etiology and provide the appropriate management regimen. The scope of laboratory medicine is broadening; clinical chemists and other laboratorians are tasked with directing broader clinical pathology sections, including Core lab hematology. Understanding the testing dynamics, diagnostic criteria and management of hematological diseases is fundamental to attaining success in consulting with providers to manage diseases such as sideroblastic anemia. Via a relevant case study, we explore the etiology, workup, symptoms, and treatment of myelodysplastic syndrome-induced sideroblastic anemia.